Puavilai S, Kunavisarut S, Vatanasuk M, Timpatanapong P, Sriwong S T, Janwitayanujit S, Nantiruj K, Totemchokchyakarn K, Ruangkanchanasetr S
Department of Medicine, Ramathibodi Hospital Medical School, Mahidol University, Bangkok, Thailand.
Int J Dermatol. 1999 Dec;38(12):934-7. doi: 10.1046/j.1365-4362.1999.00849.x.
Chloroquine has been prescribed for the treatment of various diseases. The most serious side-effect of chloroquine is retinopathy. The frequency of occurrence of retinopathy varies from 0.001 to 40% depending on the criteria used. The purpose of this study was to evaluate the incidence of ocular toxicity from chloroquine treatment among Thai patients.
A retrospective study was carried out in patients treated with chloroquine at Ramathibodi Hospital over the past 10 years (1987-1997). Patients eligible for review were followed by ophthalmic examination by an ophthalmologist for at least 6 months after starting treatment.
One hundred and fifty-five patients were studied. Nineteen were men and 136 were women. They ranged in age from 10 to 70 years. Most patients received 250 mg of chloroquine per day. The duration of treatment varied from 6 months to 14 years, and the cumulative dose of chloroquine ranged from 26 to 1771 g. Fourteen patients (9%) had only corneal deposition, while 22 (14.2%) developed retinopathy. There were no correlations between corneal deposits or retinopathy and age, sex, duration of treatment, or cumulative dose of chloroquine.
The present study confirms the finding reported by Mackenzie (Am J Med 1983; 75 (Suppl 1A): 40-45) that retinopathy is not related to the duration of treatment and cumulative dose of chloroquine. Based on our finding that retinopathy can be detected as early as 9 months after starting chloroquine therapy, we recommend routine ophthalmic examination before treatment and every 6 months thereafter.
氯喹已被用于治疗多种疾病。氯喹最严重的副作用是视网膜病变。视网膜病变的发生率因所采用的标准不同而在0.001%至40%之间变化。本研究的目的是评估泰国患者接受氯喹治疗后眼部毒性的发生率。
对过去10年(1987 - 1997年)在拉玛提波地医院接受氯喹治疗的患者进行回顾性研究。符合审查条件的患者在开始治疗后由眼科医生进行至少6个月的眼科检查随访。
共研究了155例患者。其中男性19例,女性136例。年龄范围为10至70岁。大多数患者每天服用250毫克氯喹。治疗时间从6个月到14年不等,氯喹的累积剂量从26克到1771克不等。14例患者(9%)仅有角膜沉着,而22例(14.2%)出现视网膜病变。角膜沉着或视网膜病变与年龄、性别、治疗时间或氯喹累积剂量之间均无相关性。
本研究证实了麦肯齐(《美国医学杂志》1983年;75(增刊1A):40 - 45)所报道的结果,即视网膜病变与氯喹的治疗时间和累积剂量无关。基于我们发现视网膜病变在开始氯喹治疗后9个月即可被检测到这一结果,我们建议在治疗前及此后每6个月进行常规眼科检查。